Additionally, in the LUX-Lung 8 clinical trial, which included patients with stage IIIB/IV lung squamous cell carcinoma progressing after platinum-based chemotherapy, patients with ERBB4 mutations showed a trend toward better PFS [HR = 0.21 (0.02–1.94)] and OS [HR = 0.22 (0.05–1.04)] when treated with afatinib than erlotinib; however, the number of patients in this subgroup was small ( n = 14), and other treatment comparators were lacking 160 .
← all excerpts
Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
1
—
—